The Hemangiomas drugs in development market research report provides comprehensive information on the therapeutics under development for Hemangiomas, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hemangiomas. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hemangiomas and features dormant and discontinued products.
GlobalData tracks 14 drugs in development for Hemangiomas by 13 companies/universities/institutes. The top development phase for Hemangiomas is preclinical with four drugs in that stage. The Hemangiomas pipeline has 12 drugs in development by companies and two by universities/ institutes. Some of the companies in the Hemangiomas pipeline products market are: Cervello Therapeutics, Wuhan Kefu New Drug and Arkayli Biopharma.
The key targets in the Hemangiomas pipeline products market include Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1), Beta 2 Adrenergic Receptor (Beta 2 Adrenoreceptor or ADRB2), and Beta 1 Adrenergic Receptor (Beta 1 Adrenoreceptor or ADRB1).
The key mechanisms of action in the Hemangiomas pipeline product include Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) Inhibitor with four drugs in Phase I. The Hemangiomas pipeline products include three routes of administration with the top ROA being Oral and two key molecule types in the Hemangiomas pipeline products market including Small Molecule, and Recombinant Protein.
Hemangiomas overview
Hemangiomas are the most common benign tumors in infants also known as strawberry marks. It is a non-cancerous vascular tumors caused by endothelial cell proliferation. Strawberry like birth marks appears on the skin within one to three weeks after the birth in around 4-5% of newborns. Most of the hemangiomas subsides without treatment and mostly occurs in premature infants. Superficial hemangioma, deep hemangioma, and combination of both are the three types of hemangiomas. Physical examination of the skin, biopsy tests and laboratory examination to evaluate the levels of GLUT 1 and imaging studies MRI, CT scan are done. As the condition gets subsided on its own no treatment is necessary but in complicated cases beta blockers, oral prednisone with drug adjustment and oral and topical corticosteroids.
For a complete picture of Hemangiomas’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
